Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-03-07
2006-03-07
Andres, Janet L. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C424S009200
Reexamination Certificate
active
07008921
ABSTRACT:
Proteolytic enzymes are involved in generation of a number of endogenous angiogenesis inhibitors and it has been shown that urokinase-activated plasmin can process plasminogen to release an angiogenesis inhibitor, K1–5 (protease-activated kringles 1–5). However, this proteolytic protein (proteolytic K1–5) cannot be secreted (exported) from cells and thus is limited in its application as a therapeutic. The present inventor has now engineered a recombinant protein derived from plasminogen which is folded correctly such that it can be secreted from cells in which it is expressed. The inventor surprisingly found that in order to fold correctly such that it can be secreted, the recombinant protein must comprise a secretory signal peptide and a pre-activation peptide derived from plasminogen.
REFERENCES:
patent: 4544545 (1985-10-01), Ryan et al.
patent: 5187098 (1993-02-01), Malke et al.
patent: 5200340 (1993-04-01), Foster et al.
patent: 5637492 (1997-06-01), Dawson et al.
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5801146 (1998-09-01), Davidson
patent: 5854221 (1998-12-01), Cao et al.
patent: 5945403 (1999-08-01), Folkman et al.
patent: 5972896 (1999-10-01), Davidson
patent: 5981484 (1999-11-01), Davidson
patent: 6057122 (2000-05-01), Davidson
patent: 6080728 (2000-06-01), Mixson
patent: 6107473 (2000-08-01), Albone et al.
patent: 6200954 (2001-03-01), Ge et al.
patent: 6218517 (2001-04-01), Suzuki
patent: 6251867 (2001-06-01), Davidson
patent: WO 94/00483 (1994-01-01), None
patent: WO 95/29242 (1995-11-01), None
patent: WO 97/23500 (1997-07-01), None
patent: WO 97/41824 (1997-11-01), None
patent: WO 96/15843 (1998-04-01), None
patent: WO 98/15574 (1998-04-01), None
patent: WO 99/00420 (1998-06-01), None
patent: WO 98/54217 (1998-12-01), None
patent: WO 99/11788 (1999-03-01), None
patent: WO 99/16889 (1999-04-01), None
patent: WO 99/26480 (1999-06-01), None
patent: WO 99/29861 (1999-06-01), None
patent: WO 99/32143 (1999-07-01), None
patent: WO 99/35248 (1999-07-01), None
patent: WO 99/39702 (1999-08-01), None
patent: WO 99/51638 (1999-10-01), None
patent: WO 99/61464 (1999-12-01), None
patent: WO 00/03726 (2000-01-01), None
patent: WO 00/04052 (2000-01-01), None
patent: WO 00/06759 (2000-02-01), None
patent: WO 00/10506 (2000-03-01), None
patent: WO 00/61179 (2000-04-01), None
patent: WO 00/31244 (2000-06-01), None
patent: WO 00/47729 (2000-08-01), None
patent: WO 00/48595 (2000-08-01), None
patent: WO 01/44294 (2001-06-01), None
Petersen et al. (1990), Characterization of the Gene for Human Plasminogen, a Key Proenzyme in the Fibrinolytic System, J. Biol. Chem. 265(11): 6104-6111.
Arap et al. (1998), Curr. Opin. Oncol. 10(6): 560-565.
Rippmann et al. (2000), J. Biochem. 349: 805-812.
Folkman, J., “Tumor angiogenesis: Therapeutic implications”; N. Engl. Jour. Med., 285: 1182-1186 (1971).
Kim, K.J. et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo”; Nature, 362: 841-844 (1993).
Hori, A. et al., “Suppression of Solid Tumor Growth by Immunoneutralizing Monoclonal Antibody Against Human Basis Fibroblast Growth Factor”; Cancer Research, 51: 6180-6184 (1991).
Ingber, D. et al., “Anaioinhibins: Synthetic analogues of fumagillin which inhibit angiogenesis and suppress tumour growth”; Nature, 48: 555-557 (1990).
Arap, W. et al., “Cancer Treatment by Targeted Drug Deliver to Tumor Vasculature in a Mouse Model”; Science, 279: 377-380 (1998).
Jain, R.K. et al., “Quantitative angiogenesis assays: progress and problems”; Nat. Med. 3: 1203-1208 (1997).
Cao, R. et al., “Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis”; Proc. Natl. Acad. Sci. USA, 96: 5728-5733 (1999).
Cao, R. et al., “Interleukin-18 acts as an angiogenesis and tumor suppressor”; FASEB J., 13: 2195-2202 (1999).
Cao, Y. et al., “Angiogenesis inhibited by drinking tea”; Nature, 381: 398 (1999).
Petros, A.M. et al., “Analysis of the aliphatic1H-NMR spectrum of plasminogen kringle 4”; Eur. J. Biochem, 170: 549-563 (1988).
Schaller, J., “Structural Aspects of the Plasminogen of Various Species”; Enzyme, 40: 63-69 (1988).
Ramesh, V. et al., “The aromatic1H-NMR spectrum of plasminogen kringle 4”; Eur. J. Biochem., 159: 581-595 (1986).
Schaller, J. et al., “Complete amino acid sequence of bovine plasminogen”; Eur. J. Biochem., 149: 267-278 (1985).
Cao, Y. et al. “Expression of Angiostatin cDNA in a Murine Fibrosarcoma Suppresses Primary Tumor Growth and Produces Long-Term Dormancy of Metastases”; J. Clin. Invest., 101(5): 1055-1063 (1998).
Cao, Y. “Endogenous Angiogenesis Inhibitors: Angiostatin, Endostatin and Other Proteolytic Fragments”; Progress in Molecular and Subcellular Biology, 20: 161-166 (1998).
Cao, Y. “Therapeutic potentials of angiostatin in the treatment of cancer”; Haematologica, 84(7): 643-650 (1999).
Cao, Y. “Angiostatin: a plasminogen-related growth inhibitor”; Angiostatin—General discussion IV, pp. 247-251.
O'Reilly, M.S. et al. “Endogenous inhibitors of angiogenesis”; Proceedings of the American Association for Cancer Research, 37: 669 (1996) [Abstract].
O'Reilly, M.S. et al. “Angiostatin: A Circulating Endothelial Cell Inhibitor That Suppresses Angiogenesis and Tumor Growth”; Cold Spring Harbor Symposia on Quantitative Biology, LIX : 471-482 (1994).
Tanaka, T. et al. “Viral Vector-targeted Antiangiogenic Gene Therapy Utilizing an Angiostatin Complementary DNA”; Cancer Research, 58: 3362-3369 (1998).
Cao, Y. “Antiangiogenic gene therapy”; Gene Therapy and Regulation, 1(2): 123-139 (2000).
Cao, Y. “Endogenous angiogenesis inhibitors and their therapeutic implications”; The International Journal of Biochemistry & Cell Biology, 33: 357-369 (2001).
Cao, Y. et al. “Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth”; The Journal of Biological Chemistry, 272(36): 22924-22928 (1997).
O'Reilly, M.S. et al. “Angiostatin: A Novel angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma”; Cell, 79: 315-328 (1994).
Wu, H-L, et al., “Interaction of Plasminogen and Fibrin in Plasminogen Activation”, Journal of Biological Chemistry, 265:19658-19664 (1990).
Cao, Y., et al., “Kringle Domains of Human Angiostatin”, Journal of Biological Chemistry, 271:29461-29467 (1996).
Forsgren, M., et al., “Molecular cloning and characterization of a full-length cDNA clone for human plasminogen”, FEBS Letters 213:254-260 (1987).
Friezner, S.J., et al., “Characterization of the cDNA Coding for Mouse Plasminogen and Localization of the Gene to Mouse Chromosome 17”, Genomics 8:49-61 (1990).
Andres Janet L.
Chandra Gyan
Dann Dorfman Herrell and Skillman
Karolinska Innovations AB
Rigaut Kathleen D.
LandOfFree
Materials and methods relating to endothelial cell growth... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods relating to endothelial cell growth..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods relating to endothelial cell growth... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3525511